Dear Shareholders,
On April 15, 2019, Metropolis achieved a significant milestone by
getting listed on BSE Limited & National Stock Exchange of India Ltd. With great pride
and enthusiasm,
I am pleased to present to you our Annual Report for 2023-24, marking
our fifth year as a publicly listed company.
As a brand, Metropolis has believed in pursuing excellence, investing
in scientific innovation and technological advancements within the diagnostic industry.
This past year, in particular, has been quite remarkable, with the Company pushing the
boundaries to achieve many key milestones. Your steadfast support has been the cornerstone
of our success, and together, we are making good progress in advancing healthcare
solutions. Thank you for your trust and confidence in our vision.
Commitment to Sustainability and Social Responsibility
Sustainability is at the heart of everything we do. We are dedicated to
minimizing our environmental impact by integrating cutting-edge technologies and best
practices. From managing biomedical waste to implementing biodegradable solutions,
enhancing energy efficiency, and conserving water, every step we take aims to preserve our
planet. We prioritize the well-being of our employees, ensuring their health, wellness,
and safety are top priorities. Quality care, patient satisfaction, and maintaining
stringent data privacy further underscore our commitment to excellence in healthcare.
We have always been passionate about fostering diversity and inclusion.
With 43% of our workforce comprising women, we are dedicated to achieving gender balance
with a 50:50 ratio by 2028. We are proud that Metropolis Healthcare is the first in Indian
diagnostics chain space to earn the 'Great Place to Work For' certification, a testament
to our inclusive culture.
Our CSR initiatives like MedEngage, Too Shy to Ask (TSTA), and our
Preventive Healthcare Programs are dear to us. They reflect our genuine commitment to
making a positive impact in society. We are happy to inform you that our MedEngage
Scholarship Program has received three prestigious awards from organizations such as
NATHealth, Assocham, and Business World.
This embodies our dedication to nurturing the young medical talent and
empowerment in India. Through our Adolescent Reproductive and Sexual Health (ARSH)
program, the physical outreach component of 'Too Shy to Ask' (TSTA), we partner with NGOs
to raise awareness about adolescent health issues. Our Swasthya Saheli initiative, in
collaboration with Bharat Cares, has empowered 61,603 girls and trained over 893 teachers
and 467 Kishori Manch members across Nandurbar and Pune districts in Maharashtra.
This program addresses crucial topics such as anemia, reproductive
health, nutrition, and adolescent rights. We are also deeply honored by recognition from
Government of Maharashtra's Brihanmumbai Municipal Corporation for our contributions to
the Pradhan Mantri TB Mukt Bharat Abhiyan. These accolades affirm our commitment to
delivering exceptional services and driving positive change, reinforcing our leadership in
healthcare and corporate responsibility.
Championing Strong Governance
Metropolis Healthcare places a high priority on strong governance to
ensure accountability and transparency. Our diverse Board of Directors, bringing varied
backgrounds and expertise, consistently upholds the highest governance standards. We
adhere rigorously to best practices both internally and externally, promoting sound
decision-making and ethical conduct. By prioritizing diversity, we actively report our
progress, aligning with our core values and bolstering our business achievements. Our
dedication to ethical practices not only fosters positive impact but also reinforces our
competitive advantage, paving the way for a brighter future for all stakeholders.
Advancing Clinical and Scientific Frontiers
Over four decades, Metropolis has built a reputation for scientific
leadership and has become the diagnostic partner of choice for clinicians and specialists.
Our commitment to innovation drives advancements in science and technology. Our aim is to
establish Metropolis as a trusted knowledge hub for medical professionals and patients,
offering state-of-the-art diagnostic solutions and invaluable healthcare insights.
Through our Metropolis Innovation Cell, we have integrated Molecular
Genomics, Artificial Intelligence, and Next Generation Sequencing to offer a suite of
advanced diagnostic tests. In the fiscal year 2023-24, we launched over 100 advanced
tests, including Comprehensive testing for food and drug allergies using AI, Syndromic
Multiplex PCR Testing for infectious diseases, and Next Generation Sequencing-based tests
for various conditions, including predictive biomarkers for cancer immunotherapy.
Our commitment to personalized care is ingrained in our approach to
morphological-to-molecular diagnostics. By combining surgical pathology reports with
cutting-edge tests and digital pathology capabilities, we deliver precise diagnostic
insights and comprehensive patient care outcomes. With ongoing investments in research and
development, we are steadfast in our mission to provide accessible, affordable, and
dependable healthcare solutions nationwide.
At Metropolis, we're not just advancing diagnostics; we're empowering
healthcare providers with the tools they need to enhance patient outcomes and improve
lives every day.
Closing Note
As we reflect on the milestones and achievements of the past year, I
extend my deepest gratitude to our shareholders, employees, partners, and customers for
their unwavering support and trust. I also want to thank our Board for their invaluable
guidance.
Looking ahead, I am confident in our continued ability to lead the
diagnostics industry with excellence, integrity, and a commitment to positive change.
Thank you for being an integral part of Metropolis' journey. We look forward to achieving
even greater success together.
Sincerely,
Dr. Sushil Shah
Founder & Chairman